Rheumatoid arthritis relapse in patients with other iatrogenic immunodeficiency-associated lymphoproliferative disorders and its treatment

References

• Kameda H, Fujii T, Nakajima A, Koike R, Sagawa A, Kanbe K, et al. Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Mod Rheumatol. 2019;29(1):31–40.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL, Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;79(6):685–699. 2019.
   Google Scholar
• Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17:212.
   PubMed Web of Science ®Google Scholar
• Immunodeficiency-associated lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008. p. 335–51.
   Google Scholar
• Harigai M. Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: a review of the literature and current perspective. Mod Rheumatol. 2018;28(1):1–8.
   PubMed Web of Science ®Google Scholar
• Katsuyama T, Sada KE, Yan M, Zeggar S, Hiramatsu S, Miyawaki Y, et al. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents. Mod Rheumatol. 2017;27(5):773–7.
   PubMed Web of Science ®Google Scholar
• Kameda T, Dobashi H, Miyatake N, Inoo M, Onishi I, Kurata N, et al. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2014;66(9):1302–9.
   PubMed Web of Science ®Google Scholar
• Nakano K, Saito K, Nawata A, Hanami K, Kubo S, Miyagawa I, et al. Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferativedisorders without regression after methotrexate withdrawal and treatment for arthritis afterregression of lymphoproliferative disorders. Mod Rheumatol 2021;31(1):94–100.
   Google Scholar
• Saito S, Kaneko Y, Yamaoka K, Tokuhira M, Takeuchi T. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate. Rheumatology. 2017;56(6):940–6.
   PubMed Web of Science ®Google Scholar
• Yamada K, Oshiro Y, Okamura S, Fujisaki T, Kondo S, Nakayama Y, et al. Clinicopathological characteristics and rituximab addition to cytotoxic therapies in patients with rheumatoid arthritis and methotrexate-associated large B lymphoproliferative disorders. Histopathology 2015;67(1):70–80.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.
   PubMed Web of Science ®Google Scholar
• Takanashi S, Aisa Y, Ito C, Arakaki H, Osada Y, Amano Y, et al. Clinical characteristics of methotrexate-associated lymphoproliferative disorders: relationship between absolute lymphocyte count recovery and spontaneous regression. Rheumatol Int. 2017;37(10):1629–33.
   PubMed Web of Science ®Google Scholar
• Madsen OR. Is DAS28-CRP with three and four variables interchangeable in individual patients selected for biological treatment in daily clinical practice? Clin Rheumatol. 2011;30(12):1577–82.
   PubMed Web of Science ®Google Scholar
• Kelaïdi C, Tulliez M, Lecoq-Lafon C, Pham XV, Kahan A, Dreyfus F, et al. Long-term remission of an EBV-positive B cell lymphoproliferative disorder associated with rheumatoid arthritis under methotrexate with anti-CD20 monoclonal antibody (Rituximab) monotherapy. Leukemia 2002;16(10):2173–4.
   PubMed Web of Science ®Google Scholar
• Kawano N, Ono N, Kawano S, Kuriyama T, Yoshida S, Inoue S, et al. Clinical features and outcomes of 9 patients with immunodeficiency-associated lymphoproliferative disorders treated at a single institution. J Clin Exp Hematop. 2014;54(3):187–96.
   PubMedGoogle Scholar
• Kawano N, Ono N, Yoshida S, Kuriyama T, Yamashita K, Beppu K, et al. Successful treatment of immunodeficiency-associated EBV-negative lymphoproliferative disorders in rheumatoid arthritis by methotrexate withdrawal and prevention of its relapse by rituximab administration. J Clin Exp Hematop. 2012;52(3):193–8.
   PubMedGoogle Scholar
• Tony HP, Roll P, Mei HE, Blümner E, Straka A, Gnuegge L, et al. Combination of B cell biomarkers as independent predictors of response in patients with rheumatoid arthritis treated with rituximab. Clin Exp Rheumatol. 2015;33(6):887–94.
   PubMed Web of Science ®Google Scholar
• Gardette A, Ottaviani S, Tubach F, Roy C, Nicaise-Roland P, Palazzo E, et al. High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis. Joint Bone Spine. 2014;81(5):416–20.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Fabris M, Pontarini E, Salvin S, Zabotti A, Benucci M, et al. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. Ann Rheum Dis. 2014;73(4):716–21.
   PubMed Web of Science ®Google Scholar
• Narvaez J, Díaz-Torné C, Ruiz JM, Hernandez MV, Torrente-Segarra V, Ros S, et al. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs. Clin Exp Rheumatol. 2011;29(6):991–7.
   PubMed Web of Science ®Google Scholar
• Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011;70(9):1575–80.
   PubMed Web of Science ®Google Scholar
• Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Le Loët X, et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum. 2011;63(4):933–8.
   PubMedGoogle Scholar
• Magnusson M, Brisslert M, Zendjanchi K, Lindh M, Bokarewa MI. Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment. Rheumatology (Oxford). 2010;49(10):1911–9.
   PubMed Web of Science ®Google Scholar
• Valleala H, Kauppi MJ, Kouri VP, Korpela M. Epstein-Barr virus in peripheral blood is associated with response to rituximab therapy in rheumatoid arthritis patients. Clin Rheumatol. 2015;34(8):1485–8.
   PubMed Web of Science ®Google Scholar
• Hoshida Y, Xu JX, Fujita S, Nakamichi I, Ikeda J, Tomita Y, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007;34(2):322–31.
   PubMed Web of Science ®Google Scholar
• Feng WH, Cohen JI, Fischer S, Li L, Sneller M, Goldbach-Mansky R, et al. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst. 2004;96(22):1691–702.
   PubMedGoogle Scholar
• Berti A, Felicetti M, Peccatori S, Bortolotti R, Guella A, Vivaldi P, et al. EBV-induced lymphoproliferative disorders in rheumatic patients: a systematic review of the literature. Joint Bone Spine. 2018;85(1):35–40.
   PubMed Web of Science ®Google Scholar
• Balandraud N, Texier G, Massy E, Muis-Pistor O, Martin M, Auger I, et al. Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis - a three years retrospective study. PLoS One. 2017;12(2):e0171623.
   PubMed Web of Science ®Google Scholar
• Balandraud N, Guis S, Meynard JB, Auger I, Roudier J, Roudier C. Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase Epstein-Barr virus load in patients with rheumatoid arthritis. Arthritis Rheum. 2007;57(5):762–7.
   PubMed Web of Science ®Google Scholar
• Dixon WG, Watson KD, Lunt M, Mercer LK, Hyrich KL, Symmons DP. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken). 2010;62(6):755–63.
   PubMed Web of Science ®Google Scholar
• Tokuhira M, Watanabe R, Nemoto T, Sagawa M, Tomikawa T, Tamaru J, et al. Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis. Leuk Lymphoma. 2012;53(4):616–23.
   PubMed Web of Science ®Google Scholar
• Kondo M, Murakawa Y, Moriyama M, Honda M, Sugiura T, Onoda K, et al. Distinct decrease in peripheral lymphocytes in EBER- positive cases of MTX-LPD. Mod Rheumatol 2021;31(1):88–93.
   Google Scholar